Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Memory-Like NK Cells: Remembering a Previous Activation by Cytokines and NK Cell Receptors.

Pahl JHW, Cerwenka A, Ni J.

Front Immunol. 2018 Nov 28;9:2796. doi: 10.3389/fimmu.2018.02796. eCollection 2018. Review.

2.

NK-cell responses are biased towards CD16-mediated effector functions in chronic hepatitis B virus infection.

Schuch A, Zecher BF, Müller PA, Correia MP, Daul F, Rennert C, Tauber C, Schlitt K, Boettler T, Neumann-Haefelin C, Hengel H, Pircher H, Cerwenka A, Thimme R, Hofmann M.

J Hepatol. 2019 Mar;70(3):351-360. doi: 10.1016/j.jhep.2018.10.006. Epub 2018 Oct 18.

3.

Checkpoint inhibition: NK cells enter the scene.

Stojanovic A, Cerwenka A.

Nat Immunol. 2018 Jul;19(7):650-652. doi: 10.1038/s41590-018-0142-y. No abstract available.

PMID:
29915295
4.

Distinct human circulating NKp30+FcεRIγ+CD8+ T cell population exhibiting high natural killer-like antitumor potential.

Correia MP, Stojanovic A, Bauer K, Juraeva D, Tykocinski LO, Lorenz HM, Brors B, Cerwenka A.

Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):E5980-E5989. doi: 10.1073/pnas.1720564115. Epub 2018 Jun 12.

5.

NKp44-Derived Peptide Binds Proliferating Cell Nuclear Antigen and Mediates Tumor Cell Death.

Shemesh A, Kundu K, Peleg R, Yossef R, Kaplanov I, Ghosh S, Khrapunsky Y, Gershoni-Yahalom O, Rabinski T, Cerwenka A, Atlas R, Porgador A.

Front Immunol. 2018 May 23;9:1114. doi: 10.3389/fimmu.2018.01114. eCollection 2018.

6.

The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease.

Stojanovic A, Correia MP, Cerwenka A.

Front Immunol. 2018 Apr 23;9:827. doi: 10.3389/fimmu.2018.00827. eCollection 2018. Review.

7.

Natural killers join the fight against cancer.

Cerwenka A, Lanier LL.

Science. 2018 Mar 30;359(6383):1460-1461. doi: 10.1126/science.aat2184. No abstract available.

PMID:
29599226
8.

TREM-1 multimerization is essential for its activation on monocytes and neutrophils.

Carrasco K, Boufenzer A, Jolly L, Le Cordier H, Wang G, Heck AJ, Cerwenka A, Vinolo E, Nazabal A, Kriznik A, Launay P, Gibot S, Derive M.

Cell Mol Immunol. 2019 May;16(5):460-472. doi: 10.1038/s41423-018-0003-5. Epub 2018 Mar 22.

PMID:
29568119
9.

CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells.

Pahl JHW, Koch J, Götz JJ, Arnold A, Reusch U, Gantke T, Rajkovic E, Treder M, Cerwenka A.

Cancer Immunol Res. 2018 May;6(5):517-527. doi: 10.1158/2326-6066.CIR-17-0550. Epub 2018 Mar 7.

10.

Radiation effects on antitumor immune responses: current perspectives and challenges.

Walle T, Martinez Monge R, Cerwenka A, Ajona D, Melero I, Lecanda F.

Ther Adv Med Oncol. 2018 Jan 18;10:1758834017742575. doi: 10.1177/1758834017742575. eCollection 2018. Review.

11.

Invasion strategies in round goby (Neogobius melanostomus): Is bigger really better?

Brandner J, Cerwenka AF, Schliewen UK, Geist J.

PLoS One. 2018 Jan 5;13(1):e0190777. doi: 10.1371/journal.pone.0190777. eCollection 2018.

12.

A systematic approach to evaluate the influence of environmental conditions on eDNA detection success in aquatic ecosystems.

Stoeckle BC, Beggel S, Cerwenka AF, Motivans E, Kuehn R, Geist J.

PLoS One. 2017 Dec 8;12(12):e0189119. doi: 10.1371/journal.pone.0189119. eCollection 2017.

13.

Iron Induces Anti-tumor Activity in Tumor-Associated Macrophages.

Costa da Silva M, Breckwoldt MO, Vinchi F, Correia MP, Stojanovic A, Thielmann CM, Meister M, Muley T, Warth A, Platten M, Hentze MW, Cerwenka A, Muckenthaler MU.

Front Immunol. 2017 Nov 8;8:1479. doi: 10.3389/fimmu.2017.01479. eCollection 2017.

14.

KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells.

Ewen EM, Pahl JHW, Miller M, Watzl C, Cerwenka A.

Eur J Immunol. 2018 Feb;48(2):355-365. doi: 10.1002/eji.201747128. Epub 2017 Nov 29.

15.

Hepatitis C virus-induced natural killer cell proliferation involves monocyte-derived cells and the OX40/OX40L axis.

Pollmann J, Götz JJ, Rupp D, Strauss O, Granzin M, Grünvogel O, Mutz P, Kramer C, Lasitschka F, Lohmann V, Björkström NK, Thimme R, Bartenschlager R, Cerwenka A.

J Hepatol. 2018 Mar;68(3):421-430. doi: 10.1016/j.jhep.2017.10.021. Epub 2017 Nov 1.

PMID:
29100993
16.

MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells.

Breunig C, Pahl J, Küblbeck M, Miller M, Antonelli D, Erdem N, Wirth C, Will R, Bott A, Cerwenka A, Wiemann S.

Cell Death Dis. 2017 Aug 3;8(8):e2973. doi: 10.1038/cddis.2017.364.

17.

Early inflammatory players in cutanous fibrosis.

Raker V, Haub J, Stojanovic A, Cerwenka A, Schuppan D, Steinbrink K.

J Dermatol Sci. 2017 Sep;87(3):228-235. doi: 10.1016/j.jdermsci.2017.06.009. Epub 2017 Jun 15. Review.

PMID:
28655471
18.

Little association of biological trait values with environmental variables in invasive alien round goby (Neogobius melanostomus).

Cerwenka AF, Pagnotta A, Böker C, Brandner J, Geist J, Schliewen UK.

Ecol Evol. 2017 Apr 26;7(12):4076-4085. doi: 10.1002/ece3.2942. eCollection 2017 Jun.

19.

Hepatitis C Virus and Human Cytomegalovirus-Natural Killer Cell Subsets in Persistent Viral Infections.

Pollmann J, Rölle A, Hofmann M, Cerwenka A.

Front Immunol. 2017 May 17;8:566. doi: 10.3389/fimmu.2017.00566. eCollection 2017. Review.

20.

NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.

Chretien AS, Fauriat C, Orlanducci F, Rey J, Borg GB, Gautherot E, Granjeaud S, Demerle C, Hamel JF, Cerwenka A, von Strandmann EP, Ifrah N, Lacombe C, Cornillet-Lefebvre P, Delaunay J, Toubert A, Arnoulet C, Vey N, Olive D.

Oncotarget. 2017 Jul 25;8(30):49548-49563. doi: 10.18632/oncotarget.17747.

21.

Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation.

Granzin M, Wagner J, Köhl U, Cerwenka A, Huppert V, Ullrich E.

Front Immunol. 2017 Apr 26;8:458. doi: 10.3389/fimmu.2017.00458. eCollection 2017. Review.

22.

TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis.

Zysset D, Weber B, Rihs S, Brasseit J, Freigang S, Riether C, Banz Y, Cerwenka A, Simillion C, Marques-Vidal P, Ochsenbein AF, Saurer L, Mueller C.

Nat Commun. 2016 Oct 20;7:13151. doi: 10.1038/ncomms13151.

23.

Adoptively transferred natural killer cells maintain long-term antitumor activity by epigenetic imprinting and CD4+ T cell help.

Ni J, Hölsken O, Miller M, Hammer Q, Luetke-Eversloh M, Romagnani C, Cerwenka A.

Oncoimmunology. 2016 Aug 5;5(9):e1219009. eCollection 2016.

24.

Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma.

Granzin M, Stojanovic A, Miller M, Childs R, Huppert V, Cerwenka A.

Oncoimmunology. 2016 Aug 5;5(9):e1219007. eCollection 2016.

25.

HMGB1: The metabolic weapon in the arsenal of NK cells.

Cerwenka A, Kopitz J, Schirmacher P, Roth W, Gdynia G.

Mol Cell Oncol. 2016 Apr 15;3(4):e1175538. doi: 10.1080/23723556.2016.1175538. eCollection 2016 Jul.

26.

Active but not inactive granulomatosis with polyangiitis is associated with decreased and phenotypically and functionally altered CD56(dim) natural killer cells.

Merkt W, Claus M, Blank N, Hundemer M, Cerwenka A, Lorenz HM, Watzl C.

Arthritis Res Ther. 2016 Sep 13;18(1):204. doi: 10.1186/s13075-016-1098-7.

27.

The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells.

Textor S, Bossler F, Henrich KO, Gartlgruber M, Pollmann J, Fiegler N, Arnold A, Westermann F, Waldburger N, Breuhahn K, Golfier S, Witzens-Harig M, Cerwenka A.

Oncoimmunology. 2016 Jul 28;5(7):e1116674. doi: 10.1080/2162402X.2015.1116674. eCollection 2016 Jul.

28.

CD2-CD58 interactions are pivotal for the activation and function of adaptive natural killer cells in human cytomegalovirus infection.

Rölle A, Halenius A, Ewen EM, Cerwenka A, Hengel H, Momburg F.

Eur J Immunol. 2016 Oct;46(10):2420-2425. doi: 10.1002/eji.201646492. Epub 2016 Aug 29.

29.

Synergistic impacts by an invasive amphipod and an invasive fish explain native gammarid extinction.

Beggel S, Brandner J, Cerwenka AF, Geist J.

BMC Ecol. 2016 Jul 14;16:32. doi: 10.1186/s12898-016-0088-6.

30.

STAT5 Loss Awakens the Dark Force in Natural Killer Cells.

Ni J, Cerwenka A.

Cancer Discov. 2016 Apr;6(4):347-9. doi: 10.1158/2159-8290.CD-16-0247.

31.

The HMGB1 protein induces a metabolic type of tumour cell death by blocking aerobic respiration.

Gdynia G, Sauer SW, Kopitz J, Fuchs D, Duglova K, Ruppert T, Miller M, Pahl J, Cerwenka A, Enders M, Mairbäurl H, Kamiński MM, Penzel R, Zhang C, Fuller JC, Wade RC, Benner A, Chang-Claude J, Brenner H, Hoffmeister M, Zentgraf H, Schirmacher P, Roth W.

Nat Commun. 2016 Mar 7;7:10764. doi: 10.1038/ncomms10764.

32.

Natural killer cell memory in infection, inflammation and cancer.

Cerwenka A, Lanier LL.

Nat Rev Immunol. 2016 Feb;16(2):112-23. doi: 10.1038/nri.2015.9. Epub 2016 Jan 25. Review.

33.

Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease.

Vinchi F, Costa da Silva M, Ingoglia G, Petrillo S, Brinkman N, Zuercher A, Cerwenka A, Tolosano E, Muckenthaler MU.

Blood. 2016 Jan 28;127(4):473-86. doi: 10.1182/blood-2015-08-663245. Epub 2015 Dec 16.

34.

Peripheral blood natural killer cell percentages in granulomatosis with polyangiitis correlate with disease inactivity and stage.

Merkt W, Sturm P, Lasitschka F, Tretter T, Watzl C, Saure D, Hundemer M, Schwenger V, Blank N, Lorenz HM, Cerwenka A.

Arthritis Res Ther. 2015 Nov 21;17:337. doi: 10.1186/s13075-015-0851-7.

35.

Tricking the balance: NK cells in anti-cancer immunity.

Pahl J, Cerwenka A.

Immunobiology. 2017 Jan;222(1):11-20. doi: 10.1016/j.imbio.2015.07.012. Epub 2015 Jul 26. Review.

PMID:
26264743
36.

Correction: harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy.

Arnon TI, Markel G, Bar-Ilan A, Hanna J, Fima E, Benchetrit F, Galili R, Cerwenka A, Benharroch D, Sion-Vardy N, Porgador A, Mandelboim O.

PLoS One. 2015 May 4;10(5):e0128052. doi: 10.1371/journal.pone.0128052. eCollection 2015. No abstract available.

37.

Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids.

Giannattasio A, Weil S, Kloess S, Ansari N, Stelzer EH, Cerwenka A, Steinle A, Koehl U, Koch J.

BMC Cancer. 2015 May 3;15:351. doi: 10.1186/s12885-015-1321-y.

38.

Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy.

Granzin M, Soltenborn S, Müller S, Kollet J, Berg M, Cerwenka A, Childs RW, Huppert V.

Cytotherapy. 2015 May;17(5):621-32. doi: 10.1016/j.jcyt.2015.03.611.

39.

Immunology. MULT1plying cancer immunity.

Steinle A, Cerwenka A.

Science. 2015 Apr 3;348(6230):45-6. doi: 10.1126/science.aaa9842. No abstract available.

PMID:
25838370
40.

Targeting natural killer cell reactivity by employing antibody to NKp46: implications for type 1 diabetes.

Yossef R, Gur C, Shemesh A, Guttman O, Hadad U, Nedvetzki S, Miletić A, Nalbandyan K, Cerwenka A, Jonjic S, Mandelboim O, Porgador A.

PLoS One. 2015 Feb 26;10(2):e0118936. doi: 10.1371/journal.pone.0118936. eCollection 2015.

41.

Exploiting natural killer cells for therapy of melanoma.

Hölsken O, Miller M, Cerwenka A.

J Dtsch Dermatol Ges. 2015 Jan;13(1):23-9. doi: 10.1111/ddg.12557. Review. English, German.

PMID:
25640488
42.

Isotope evidence for preferential dispersal of fast-spreading invasive gobies along man-made river bank structures.

Brandner J, Auerswald K, Schäufele R, Cerwenka AF, Geist J.

Isotopes Environ Health Stud. 2015;51(1):80-92. doi: 10.1080/10256016.2014.993978. Epub 2015 Jan 2.

PMID:
25555038
43.

Antigen dependently activated cluster of differentiation 8-positive T cells cause perforin-mediated neurotoxicity in experimental stroke.

Mracsko E, Liesz A, Stojanovic A, Lou WP, Osswald M, Zhou W, Karcher S, Winkler F, Martin-Villalba A, Cerwenka A, Veltkamp R.

J Neurosci. 2014 Dec 10;34(50):16784-95. doi: 10.1523/JNEUROSCI.1867-14.2014.

44.

IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion.

Rölle A, Pollmann J, Ewen EM, Le VT, Halenius A, Hengel H, Cerwenka A.

J Clin Invest. 2014 Dec;124(12):5305-16. doi: 10.1172/JCI77440. Epub 2014 Nov 10.

45.

Chronic liver inflammation and hepatocellular carcinogenesis are independent of S100A9.

De Ponti A, Wiechert L, Stojanovic A, Longerich T, Marhenke S, Hogg N, Vogel A, Cerwenka A, Schirmacher P, Hess J, Angel P.

Int J Cancer. 2015 May 15;136(10):2458-63. doi: 10.1002/ijc.29282. Epub 2014 Nov 13.

46.

Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.

Schlecker E, Fiegler N, Arnold A, Altevogt P, Rose-John S, Moldenhauer G, Sucker A, Paschen A, von Strandmann EP, Textor S, Cerwenka A.

Cancer Res. 2014 Jul 1;74(13):3429-40. doi: 10.1158/0008-5472.CAN-13-3017. Epub 2014 Apr 29.

47.

CTLA-4 is expressed by activated mouse NK cells and inhibits NK Cell IFN-γ production in response to mature dendritic cells.

Stojanovic A, Fiegler N, Brunner-Weinzierl M, Cerwenka A.

J Immunol. 2014 May 1;192(9):4184-91. doi: 10.4049/jimmunol.1302091. Epub 2014 Mar 31.

48.

New prospects on the NKG2D/NKG2DL system for oncology.

Ullrich E, Koch J, Cerwenka A, Steinle A.

Oncoimmunology. 2013 Oct 1;2(10):e26097. Epub 2013 Oct 25. Review.

49.

Memory of infections: an emerging role for natural killer cells.

Rölle A, Pollmann J, Cerwenka A.

PLoS Pathog. 2013;9(9):e1003548. doi: 10.1371/journal.ppat.1003548. Epub 2013 Sep 26. Review. No abstract available.

50.

Bigger is better: characteristics of round gobies forming an invasion front in the Danube river.

Brandner J, Cerwenka AF, Schliewen UK, Geist J.

PLoS One. 2013 Sep 9;8(9):e73036. doi: 10.1371/journal.pone.0073036. eCollection 2013.

Supplemental Content

Loading ...
Support Center